BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1514 related articles for article (PubMed ID: 17015225)

  • 1. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversy: is Parkinson's disease a single disease entity? Yes.
    Takahashi H; Wakabayashi K
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S31-7. PubMed ID: 15885626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and alpha-synuclein].
    Iwatsubo T
    Rinsho Shinkeigaku; 1999 Dec; 39(12):1285-6. PubMed ID: 10791099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
    Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
    Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Drosophila model of Parkinson's disease.
    Feany MB; Bender WW
    Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropathological spectrum of synucleinopathies.
    Jellinger KA
    Mov Disord; 2003 Sep; 18 Suppl 6():S2-12. PubMed ID: 14502650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synphilin-1 is present in Lewy bodies in Parkinson's disease.
    Wakabayashi K; Engelender S; Yoshimoto M; Tsuji S; Ross CA; Takahashi H
    Ann Neurol; 2000 Apr; 47(4):521-3. PubMed ID: 10762166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of Parkinson's disease.
    Sherer TB; Betarbet R; Greenamyre JT
    Curr Opin Investig Drugs; 2001 May; 2(5):657-62. PubMed ID: 11569943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-synuclein, Abeta and Alzheimer's disease.
    Wirths O; Bayer TA
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):103-8. PubMed ID: 12551731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.
    Luk KC; Hyde EG; Trojanowski JQ; Lee VM
    Biochemistry; 2007 Nov; 46(44):12522-9. PubMed ID: 17927212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
    Liu IH; Uversky VN; Munishkina LA; Fink AL; Halfter W; Cole GJ
    Glycobiology; 2005 Dec; 15(12):1320-31. PubMed ID: 16037493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The mechanism of Lewy body formation in Parkinson's disease].
    Wakabayashi K; Takahashi H
    Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene.
    Yamaguchi K; Cochran EJ; Murrell JR; Polymeropoulos MH; Shannon KM; Crowther RA; Goedert M; Ghetti B
    Acta Neuropathol; 2005 Sep; 110(3):298-305. PubMed ID: 15981014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation.
    Meredith GE; Halliday GM; Totterdell S
    Parkinsonism Relat Disord; 2004 Jun; 10(4):191-202. PubMed ID: 15120093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.
    Zarranz JJ; Alegre J; Gómez-Esteban JC; Lezcano E; Ros R; Ampuero I; Vidal L; Hoenicka J; Rodriguez O; Atarés B; Llorens V; Gomez Tortosa E; del Ser T; Muñoz DG; de Yebenes JG
    Ann Neurol; 2004 Feb; 55(2):164-73. PubMed ID: 14755719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression.
    Fan Y; Limprasert P; Murray IV; Smith AC; Lee VM; Trojanowski JQ; Sopher BL; La Spada AR
    Hum Mol Genet; 2006 Oct; 15(20):3002-11. PubMed ID: 16959793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.